Abstract
Background Coronary CT angiography (CCTA) and cardiac magnetic resonance (CMR) have been used to diagnose lesion-specific ischemia in patients with coronary artery disease (CAD).
Objective The aim of this study was to investigate the diagnostic performance of CCTA-derived plaque characteristic index compared with myocardial blood flow (MBF) and myocardial perfusion reserve (MPR) derived from CMR perfusion in the assessment of lesion-specific ischemia.
Methods Between October 2020 and March 2022, consecutive patients with suspected or known CAD, who were clinically referred for ICA were prospectively enrolled. All participants sequentially underwent CCTA and CMR and invasive fractional flow reserve (FFR) within 2 weeks. The diagnostic performance of CCTA-derived plaque characteristics, CMR perfusion-derived stress MBF, and MPR were compared. Lesions with FFR ≤ 0.80 were considered to be hemodynamically significant stenosis.
Results Nighty-two patients with 141 vessels were included in this study. Plaque length, minimum luminal area, plaque area, percent area stenosis, total atheroma volume, vessel volume, lipid rich volume, spotty calcium, napkin-ring signs, stress MBF and MPR in flow-limiting stenosis group were significantly different from non-flow limiting group. The overall accuracy, sensitivity, specificity, PPV, and NPV of lesion-specific ischemia diagnosis were 61.0%, 55.3%, 63.1%, 35.6%, 79.3% for stress MBF, and 89.4%, 89.5%, 89.3%, 75.6%, 95.8% for MPR, meanwhile 82.3%, 79.0%, 84.5%, 65.2%, 91.6% for CCTA-Derived plaque characteristic index.
Conclusion In our prospective study, CCTA-derived plaque characteristics and MPR derived from CMR performed well in diagnosing lesion-specific myocardial ischemia, and were significantly better than stress MBF in stable coronary artery disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The project was supported by Shanghai Municipal Key Clinical Specialty (grant number shslczdzk03202).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Zhongshan Hospital, Fudan University, Shanghai, China, gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
